With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. Still, geopolitical uncertainties under the second Trump administration loom large over the ...
As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly weighing sales of certain units and facilities. R&D powerhouse WuXi AppTec has ...
"I just liked working with them so much that I joined them," Chen told BioWorld. Today, Chen is co-CEO of WuXi AppTec. The company, which started with a laboratory of 7,000 square feet, has grown into ...
SHANGHAI, China, October 29, 2025 (EZ Newswire) -- WuXi AppTec, opens new tab, a global contract research, development, and manufacturing organization (CRDMO), recently hosted its 2025 Investor Day, ...
A WuXi Biologics facility in Wuxi, China. WuXi AppTec and an affiliated company, WuXi Biologics, have received millions of dollars in tax incentives to build sprawling research and manufacturing sites ...
Chinese life science contracting giant WuXi AppTec is taking another step to zero in on its core offerings by hiving off two China-based subsidiaries. The Shanghai-based corporation announced on Oct.
March 28 (Reuters) - U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi AppTec (603259.SS), opens new tab had ...
WuXi Biologics is a young biologics contract development and manufacturing organization, or CDMO. It is rapidly building up capacity to become comparable in size to the top three players. It is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results